Comparing Beta Bionics (BBNX) & Its Rivals

Beta Bionics (NASDAQ:BBNX) is one of 142 publicly-traded companies in the “MED INSTRUMENTS” industry, but how does it contrast to its peers? We will compare Beta Bionics to similar companies based on the strength of its institutional ownership, risk, profitability, dividends, analyst recommendations, valuation and earnings.

Institutional and Insider Ownership

54.1% of shares of all “MED INSTRUMENTS” companies are owned by institutional investors. 14.7% of shares of all “MED INSTRUMENTS” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Beta Bionics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Beta Bionics	$65.12 million	-$54.76 million	-6.23
Beta Bionics Competitors	$1.75 billion	$200.62 million	-3.47

Beta Bionics’ peers have higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Beta Bionics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-87.89%	-35.72%	-20.69%
Beta Bionics Competitors	-182.40%	-90.47%	-20.57%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Beta Bionics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1	3	8	1	2.69
Beta Bionics Competitors	1149	3763	7082	262	2.53

Beta Bionics presently has a consensus target price of $28.22, suggesting a potential upside of 3.68%. As a group, “MED INSTRUMENTS” companies have a potential upside of 23.86%. Given Beta Bionics’ peers higher possible upside, analysts clearly believe Beta Bionics has less favorable growth aspects than its peers.

Summary

Beta Bionics peers beat Beta Bionics on 7 of the 12 factors compared.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.